Skip to main content
Top
Published in: Neurosurgical Review 6/2022

26-09-2022 | Glioma | Research

Correlation analysis of tumor purity with clinicopathological, molecular, and imaging features in high-grade gliomas

Authors: Qing Zhou, Peng Zhang, Jiangwei Man, Bin Zhang, Caiqiang Xue, Xiaoai Ke, Junlin Zhou

Published in: Neurosurgical Review | Issue 6/2022

Login to get access

Abstract

High-grade gliomas (HGG) have high malignancy, high heterogeneity, and a poor prognosis. Tumor purity is an intrinsic feature of the HGG microenvironment and an independent prognostic factor. The purpose of this study was to analyze the correlation of tumor purity with clinicopathological, molecular, and imaging features. We performed a retrospective analysis of 112 patients diagnosed with HGG (grades III and IV) in our center. Eleven regions of interest (ROI) were randomly selected on whole-slide images (WSI, 40 × magnification) based on HGG tissue paraffin sections and hematoxylin–eosin (H&E) staining. Of these 11 ROIs, five ROIs were visually estimated by pathologists and six ROIs were automatically analyzed using ImageJ software. Last, the average tumor purity (%) of the 11 ROIs was calculated. Correlation analysis of tumor purity with clinicopathological, molecular, and imaging features was conducted. Of the 112 patients included in the study, the mean tumor purity of HGG was 70.96%. There were differences in tumor purity between WHO grades III and IV; the tumor purity of grade IV patients (67.59%) was lower than that of grade III patients (76.00%) (p < 0.001). There were also differences in tumor purity between IDH1 mutant and wild type, and the tumor purity of IDH1 mutant patients was higher than that of IDH1 wild-type patients (p = 0.006). The average range of peritumoral edema was about 19.18 mm, and the diameter of edema, ADCmean, and ADCmin were negatively correlated with tumor purity(r =  − 0.236, r =  − 0.306, and r =  − 0.242; p < 0.05). The grade of HGG, IDH1 mutant/wild type, peritumoral edema, and ADC value were correlated with tumor purity. HGG grade, IDH1 mutant/wild type, peritumoral edema, and ADC value can predict tumor purity and indirectly reflect patient prognosis.
Literature
1.
go back to reference Aran D, Sirota M, Butte AJ (2015) Systematic pan-cancer analysis of tumour purity. Nat Commun 6:8971CrossRefPubMed Aran D, Sirota M, Butte AJ (2015) Systematic pan-cancer analysis of tumour purity. Nat Commun 6:8971CrossRefPubMed
2.
go back to reference Azimi V, Chang YH, Thibault G, Smith J, Tsujikawa T, Kukull B, Jensen B, Corless C, Margolin A, Gray JW (2017) Breast cancer histopathology image analysis pipeline for tumor purity estimation. Proc IEEE Int Symp Biomed Imaging 2017:1137–1140PubMedPubMedCentral Azimi V, Chang YH, Thibault G, Smith J, Tsujikawa T, Kukull B, Jensen B, Corless C, Margolin A, Gray JW (2017) Breast cancer histopathology image analysis pipeline for tumor purity estimation. Proc IEEE Int Symp Biomed Imaging 2017:1137–1140PubMedPubMedCentral
3.
go back to reference Biswas NK, Chandra V, Sarkar-Roy N, Das T, Bhattacharya RN, Tripathy LN, Basu SK, Kumar S, Das S, Chatterjee A, Mukherjee A, Basu P, Maitra A, Chattopadhyay A, Basu A, Dhara S (2015) Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM. Sci Rep 5:7915CrossRefPubMedPubMedCentral Biswas NK, Chandra V, Sarkar-Roy N, Das T, Bhattacharya RN, Tripathy LN, Basu SK, Kumar S, Das S, Chatterjee A, Mukherjee A, Basu P, Maitra A, Chattopadhyay A, Basu A, Dhara S (2015) Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM. Sci Rep 5:7915CrossRefPubMedPubMedCentral
4.
go back to reference Chang PD, Malone HR, Bowden SG, Chow DS, Gill BJA, Ung TH, Samanamud J, Englander ZK, Sonabend AM, Sheth SA, McKhann GM 2nd, Sisti MB, Schwartz LH, Lignelli A, Grinband J, Bruce JN, Canoll P (2017) A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies. AJNR Am J Neuroradiol 38(5):890–898CrossRefPubMedPubMedCentral Chang PD, Malone HR, Bowden SG, Chow DS, Gill BJA, Ung TH, Samanamud J, Englander ZK, Sonabend AM, Sheth SA, McKhann GM 2nd, Sisti MB, Schwartz LH, Lignelli A, Grinband J, Bruce JN, Canoll P (2017) A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies. AJNR Am J Neuroradiol 38(5):890–898CrossRefPubMedPubMedCentral
5.
go back to reference Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW (2017) Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol 19(6):786–795CrossRefPubMedPubMedCentral Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW (2017) Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol 19(6):786–795CrossRefPubMedPubMedCentral
6.
go back to reference Li F, Sun H, Li Y, Bai X, Dong X, Zhao N, Meng J, Sun B, Zhang D (2021) High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer. BMC Cancer 21(1):1305CrossRefPubMedPubMedCentral Li F, Sun H, Li Y, Bai X, Dong X, Zhao N, Meng J, Sun B, Zhang D (2021) High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer. BMC Cancer 21(1):1305CrossRefPubMedPubMedCentral
7.
go back to reference Li H, Li J, Zhang C, Zhang C, Wang H (2020) TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment. Cancer Med 9(19):7151–7160CrossRefPubMedPubMedCentral Li H, Li J, Zhang C, Zhang C, Wang H (2020) TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment. Cancer Med 9(19):7151–7160CrossRefPubMedPubMedCentral
8.
go back to reference Lou S, Zhang J, Yin X, Zhang Y, Fang T, Wang Y, Xue Y (2021) Comprehensive characterization of tumor purity and its clinical implications in gastric cancer. Front Cell Dev Biol 9:782529CrossRefPubMed Lou S, Zhang J, Yin X, Zhang Y, Fang T, Wang Y, Xue Y (2021) Comprehensive characterization of tumor purity and its clinical implications in gastric cancer. Front Cell Dev Biol 9:782529CrossRefPubMed
9.
go back to reference Lu X, Li C, Xu W, Wu Y, Wang J, Chen S, Zhang H, Huang H, Huang H, Liu W (2021) Malignant tumor purity reveals the driven and prognostic role of CD3E in low-grade glioma Microenvironment. Front Oncol 11:676124CrossRefPubMedPubMedCentral Lu X, Li C, Xu W, Wu Y, Wang J, Chen S, Zhang H, Huang H, Huang H, Liu W (2021) Malignant tumor purity reveals the driven and prognostic role of CD3E in low-grade glioma Microenvironment. Front Oncol 11:676124CrossRefPubMedPubMedCentral
10.
go back to reference Patel NM, Jo H, Eberhard DA, Yin X, Hayward MC, Stein MK, Hayes DN, Grilley-Olson JE (2019) Improved tumor purity metrics in next-generation sequencing for clinical practice: the integrated interpretation of neoplastic cellularity and sequencing results (IINCaSe) approach. Appl Immunohistochem Mol Morphol 27(10):764–772CrossRefPubMed Patel NM, Jo H, Eberhard DA, Yin X, Hayward MC, Stein MK, Hayes DN, Grilley-Olson JE (2019) Improved tumor purity metrics in next-generation sequencing for clinical practice: the integrated interpretation of neoplastic cellularity and sequencing results (IINCaSe) approach. Appl Immunohistochem Mol Morphol 27(10):764–772CrossRefPubMed
11.
go back to reference Pei L, Jones KA, Shboul ZA, Chen JY, Iftekharuddin KM (2021) Deep neural network analysis of pathology images with integrated molecular data for enhanced glioma classification and grading. Front Oncol 11:668694CrossRefPubMedPubMedCentral Pei L, Jones KA, Shboul ZA, Chen JY, Iftekharuddin KM (2021) Deep neural network analysis of pathology images with integrated molecular data for enhanced glioma classification and grading. Front Oncol 11:668694CrossRefPubMedPubMedCentral
12.
go back to reference Qi T, Meng X, Wang Z, Wang X, Sun N, Ming J, Ren L, Jiang C, Cai J (2021) A voxel-based radiographic analysis reveals the biological character of proneural-mesenchymal transition in glioblastoma. Front Oncol 11:595259CrossRefPubMedPubMedCentral Qi T, Meng X, Wang Z, Wang X, Sun N, Ming J, Ren L, Jiang C, Cai J (2021) A voxel-based radiographic analysis reveals the biological character of proneural-mesenchymal transition in glioblastoma. Front Oncol 11:595259CrossRefPubMedPubMedCentral
13.
go back to reference Qin Y, Feng H, Chen M, Wu H, Zheng X (2018) InfiniumPurify: an R package for estimating and accounting for tumor purity in cancer methylation research. Genes Dis 5(1):43–45CrossRefPubMedPubMedCentral Qin Y, Feng H, Chen M, Wu H, Zheng X (2018) InfiniumPurify: an R package for estimating and accounting for tumor purity in cancer methylation research. Genes Dis 5(1):43–45CrossRefPubMedPubMedCentral
14.
go back to reference Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF (2004) Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer-Am Cancer Soc 100(7):1365–1373 Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF (2004) Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer-Am Cancer Soc 100(7):1365–1373
15.
go back to reference Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E (2016) Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia 30(3):666–673CrossRefPubMed Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E (2016) Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia 30(3):666–673CrossRefPubMed
16.
go back to reference Sallman DA, Padron E (2016) Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther 9(3):89–95CrossRefPubMed Sallman DA, Padron E (2016) Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther 9(3):89–95CrossRefPubMed
17.
go back to reference Schulze Heuling E, Knab F, Radke J, Eskilsson E, Martinez-Ledesma E, Koch A, Czabanka M, Dieterich C, Verhaak RG, Harms C, Euskirchen P (2017) Prognostic relevance of tumor purity and Interaction with MGMT methylation in glioblastoma. Mol Cancer Res 15(5):532–540CrossRefPubMed Schulze Heuling E, Knab F, Radke J, Eskilsson E, Martinez-Ledesma E, Koch A, Czabanka M, Dieterich C, Verhaak RG, Harms C, Euskirchen P (2017) Prognostic relevance of tumor purity and Interaction with MGMT methylation in glioblastoma. Mol Cancer Res 15(5):532–540CrossRefPubMed
18.
go back to reference Xiong Y, Xiong Z, Cao H, Li C, Wanggou S, Li X (2020) Multi-dimensional omics characterization in glioblastoma identifies the purity-associated pattern and prognostic gene signatures. Cancer Cell Int 20:37CrossRefPubMedPubMedCentral Xiong Y, Xiong Z, Cao H, Li C, Wanggou S, Li X (2020) Multi-dimensional omics characterization in glioblastoma identifies the purity-associated pattern and prognostic gene signatures. Cancer Cell Int 20:37CrossRefPubMedPubMedCentral
19.
go back to reference Yang J, Wang J, Tian S, Wang Q, Zhao Y, Wang B, Cao L, Liang Z, Zhao H, Lian H, Ma J (2021) An integrated analysis of tumor purity of common central nervous system tumors in children based on machine learning methods. Front Genet 12:707802CrossRefPubMedPubMedCentral Yang J, Wang J, Tian S, Wang Q, Zhao Y, Wang B, Cao L, Liang Z, Zhao H, Lian H, Ma J (2021) An integrated analysis of tumor purity of common central nervous system tumors in children based on machine learning methods. Front Genet 12:707802CrossRefPubMedPubMedCentral
20.
go back to reference Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T, Wu A (2017) Tumor purity as an underlying key factor in glioma. Clin Cancer Res 23(20):6279–6291CrossRefPubMed Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T, Wu A (2017) Tumor purity as an underlying key factor in glioma. Clin Cancer Res 23(20):6279–6291CrossRefPubMed
21.
go back to reference Zhao B, Xia Y, Yang F, Wang Y, Wang Y, Wang Y, Dai C, Wang Y, Ma W (2022) Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor. Mol Med 28(1):34CrossRefPubMedPubMedCentral Zhao B, Xia Y, Yang F, Wang Y, Wang Y, Wang Y, Dai C, Wang Y, Ma W (2022) Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor. Mol Med 28(1):34CrossRefPubMedPubMedCentral
Metadata
Title
Correlation analysis of tumor purity with clinicopathological, molecular, and imaging features in high-grade gliomas
Authors
Qing Zhou
Peng Zhang
Jiangwei Man
Bin Zhang
Caiqiang Xue
Xiaoai Ke
Junlin Zhou
Publication date
26-09-2022
Publisher
Springer Berlin Heidelberg
Published in
Neurosurgical Review / Issue 6/2022
Print ISSN: 0344-5607
Electronic ISSN: 1437-2320
DOI
https://doi.org/10.1007/s10143-022-01871-8

Other articles of this Issue 6/2022

Neurosurgical Review 6/2022 Go to the issue